CY1115624T1 - Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ - Google Patents

Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ

Info

Publication number
CY1115624T1
CY1115624T1 CY20141100799T CY141100799T CY1115624T1 CY 1115624 T1 CY1115624 T1 CY 1115624T1 CY 20141100799 T CY20141100799 T CY 20141100799T CY 141100799 T CY141100799 T CY 141100799T CY 1115624 T1 CY1115624 T1 CY 1115624T1
Authority
CY
Cyprus
Prior art keywords
biological sample
detection
aggregates
antibodies
special antibodies
Prior art date
Application number
CY20141100799T
Other languages
English (en)
Inventor
Günther Staffler
Andreas Mairhofer
Achim Schneeberger
Martina Lutterova
Walter Schmidt
Frank Mattner
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of CY1115624T1 publication Critical patent/CY1115624T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Αποκαλύπτεται κάποια μέθοδος για την ανίχνευση ειδικών αντισωμάτων για τα Αβ σε κάποιο βιολογικό δείγμα, η οποία αποτελείται από τα παρακάτω βήματα: -την επαφή του δείγματος με Αβ-συσσωματώματα ή με σωματίδια που περιλαμβάνουν επιφάνειες όμοιες με το Αβ-συσσωμάτωμα και επιτρέποντας τα ειδικά αντισώματα για το Αβ να δεσμεύονται στα Αβ-συσσωματώματα, και -την ανίχνευση των ειδικών αντισωμάτων για το Αβ που είναι δεσμευμένο στα Αβ-συσσωματώματα με κάποια τεχνική μονήρους ανίχνευσης, κατά προτίμηση με επιλογή κυττάρων μέσω φθορισμού (fluorescence activated cell sorting, FACS).
CY20141100799T 2011-10-04 2014-10-03 Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ CY1115624T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11183842.1A EP2579042B1 (en) 2011-10-04 2011-10-04 Method for detecting Aß-specific antibodies in a biological sample

Publications (1)

Publication Number Publication Date
CY1115624T1 true CY1115624T1 (el) 2017-01-04

Family

ID=46888451

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100799T CY1115624T1 (el) 2011-10-04 2014-10-03 Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ

Country Status (24)

Country Link
US (2) US9625459B2 (el)
EP (3) EP2579042B1 (el)
JP (2) JP2014529088A (el)
KR (2) KR20140073568A (el)
CN (2) CN103842824A (el)
AR (1) AR088108A1 (el)
AU (2) AU2012320767A1 (el)
BR (2) BR112014008088A2 (el)
CA (2) CA2850843A1 (el)
CY (1) CY1115624T1 (el)
DK (2) DK2579042T3 (el)
ES (2) ES2496341T3 (el)
HK (1) HK1178601A1 (el)
HR (1) HRP20140937T1 (el)
IL (2) IL231057A0 (el)
MX (2) MX2014003983A (el)
PL (2) PL2579042T3 (el)
PT (1) PT2579042E (el)
RS (1) RS53496B1 (el)
RU (2) RU2014117677A (el)
SG (2) SG11201400229XA (el)
SI (1) SI2579042T1 (el)
SM (1) SMT201400145B (el)
WO (2) WO2013050248A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR101658620B1 (ko) * 2014-12-02 2016-09-23 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR20170108203A (ko) * 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
KR101871895B1 (ko) * 2016-04-20 2018-06-28 한국과학기술연구원 응집 단백질의 고감도 광 산화 증폭 면역 분석을 통한 체액기반의 퇴행성 신경질환 진단 방법
EP3242134A1 (en) * 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
KR101989383B1 (ko) * 2017-04-04 2019-06-14 조선대학교산학협력단 알츠하이머성 치매의 조기진단을 위한 펩타이드 프로브
WO2020045962A1 (ko) * 2018-08-27 2020-03-05 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
KR102108171B1 (ko) * 2018-08-27 2020-05-08 광주과학기술원 알츠하이머성 치매 진단용 펩타이드 바이오마커
CN113063949A (zh) * 2021-03-23 2021-07-02 中国医学科学院输血研究所 一种血浆中特异性IgM抗体的定量测定方法
CN113075398A (zh) * 2021-03-23 2021-07-06 中国医学科学院输血研究所 一种血浆中特异性IgG抗体的定量测定方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1996012544A1 (en) 1994-10-19 1996-05-02 The General Hospital Corporation A DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF Aβ ABNORMALITIES
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2004074837A1 (en) * 2003-02-24 2004-09-02 Digitalbiotech Co., Ltd. Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer’s disease using same
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102005006217B4 (de) * 2005-02-07 2007-08-16 Universitätsklinikum Hamburg-Eppendorf Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum
NZ560689A (en) * 2005-03-05 2010-12-24 Abbott Gmbh & Co Kg Screening method, process for purifying of non-diffusible abeta oligomer, selective antibodies against said non-diffusible abeta oligomers and a process for manufacturing of said antibodies
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
KR101965124B1 (ko) 2005-07-08 2019-04-02 디에스엠 아이피 어셋츠 비.브이. 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
JP2010515717A (ja) * 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
WO2009051599A1 (en) * 2007-10-19 2009-04-23 The Regents Of The University Of California Use of biomarkers of alzheimer's disease for diagnostic tests and drug screening
US7771957B2 (en) * 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EP2310032A2 (en) 2008-06-12 2011-04-20 Affiris AG Compounds for treating symptoms associated with parkinson's disease
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
WO2010099199A1 (en) 2009-02-24 2010-09-02 Gibbons Winton G Detection of complexes of tau and amyloid
WO2010128139A1 (en) 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
WO2011106732A1 (en) * 2010-02-25 2011-09-01 Wyeth Llc Pet monitoring of ab-directed immunotherapy

Also Published As

Publication number Publication date
WO2013050248A1 (en) 2013-04-11
MX2014003984A (es) 2014-05-07
EP2579042B1 (en) 2014-07-09
ES2692185T3 (es) 2018-11-30
PL2579042T3 (pl) 2014-12-31
EP2764367A1 (en) 2014-08-13
EP2579042A1 (en) 2013-04-10
AU2012320766A1 (en) 2014-03-13
PL2764367T3 (pl) 2019-04-30
EP2764367B1 (en) 2018-07-25
SMT201400145B (it) 2014-11-10
EP2764368A1 (en) 2014-08-13
KR20140069346A (ko) 2014-06-09
RU2014117671A (ru) 2015-11-10
AR088108A1 (es) 2014-05-07
BR112014008089A2 (pt) 2017-04-18
AU2012320766B2 (en) 2017-09-21
US20140242727A1 (en) 2014-08-28
HK1178601A1 (en) 2013-09-13
ES2496341T3 (es) 2014-09-18
DK2579042T3 (da) 2014-07-21
JP2014529088A (ja) 2014-10-30
RS53496B1 (en) 2015-02-27
SG11201400229XA (en) 2014-05-29
US20140234877A1 (en) 2014-08-21
DK2764367T3 (en) 2018-10-29
CN103842825B (zh) 2016-04-20
IL231057A0 (en) 2014-03-31
CA2850840A1 (en) 2013-04-11
KR20140073568A (ko) 2014-06-16
JP6162127B2 (ja) 2017-07-12
RU2014117677A (ru) 2015-11-10
CN103842825A (zh) 2014-06-04
BR112014008088A2 (pt) 2017-04-18
IL231620A0 (en) 2014-05-28
MX2014003983A (es) 2014-05-07
HRP20140937T1 (hr) 2014-12-05
SI2579042T1 (sl) 2014-09-30
JP2014529087A (ja) 2014-10-30
US9625459B2 (en) 2017-04-18
WO2013050249A1 (en) 2013-04-11
CA2850843A1 (en) 2013-04-11
AU2012320767A1 (en) 2014-03-13
CN103842824A (zh) 2014-06-04
PT2579042E (pt) 2014-09-09
SG11201400223SA (en) 2014-05-29

Similar Documents

Publication Publication Date Title
CY1115624T1 (el) Μεθοδος ανιχνευσης σε καποιο βιολογικο δειγμα των ειδικων αντισωματων για τα αβ
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1121291T1 (el) Ανοσοδοκιμασιες ενισχυσης σηματος
MX366275B (es) Metodos para detectar y medir la agregacion.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CY1118748T1 (el) Πολυπλεγμενοι προσδιορισμοι βασιζομενοι σε απταμερη
MX2019015016A (es) Ensayos para la deteccion de una sola molecula y uso de los mismos.
BR112015023239A2 (pt) ensaio de combinação antígeno-anticorpo e métodos e composições para uso do mesmo
BR112012016119A2 (pt) detecção de carga biológica viva com o uso de micropartículas
UY34343A (es) Proteinas de unión al antígeno cd27l
AR083295A1 (es) Metodo para activar celulas t auxiliares
GB201202223D0 (en) Immunoassay for pyrrolidinophenones
NZ605449A (en) Anti-neuropilin antibodies and methods of use
CY1123180T1 (el) Συστημα ανιχνευσης που αξιοποιει αλυσιδωτη αντιδραση πολυμερασης
FR2970102B1 (fr) Detecteur de fumee
DK2357465T3 (da) Anordning til bestemmelse af fotoluminescens-kvanteudbyttet og yderligere optiske egenskaber i en prøve
CY1120220T1 (el) Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση
WO2014144725A3 (en) Melatonin monoclonal antibody, detection, methods and uses thereof
BR112014032677A2 (pt) ensaios rápido para ativação de célula t por medições de rna usando citometria de fluxo
CL2011002973A1 (es) Metodo para detectar anticuerpos en una muestra que comprende contactar una muestra con un soporte que tiene fijado un peptoide; kit para detectar anticuerpos que son indicativos de una enfermedad neurodegenerativa.
MX2014015088A (es) Anticuerpos anti-tofacitinib y usos de los mismos para monitorear farmacos.
WO2011127001A3 (en) Quantum dot-based optical sensors for rapid detection and quantitative analysis of biomolecules and biological materials
MX2023005689A (es) Inmunoensayo para detectar quininogeno escindido de alto peso molecular.
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
CL2016001073A1 (es) Ácidos nucleicos y métodos para detectar microorganismos patógenos y benéficos.